A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus

Diabetologia

Volumn 56, Issue 2, 2013, Pages 259-267

  Roscioni, S S ^a   De Zeeuw, D ^a   Hellemons, M E ^a   Mischak, H ^b,c   Zurbig P ^c   Bakker, S J L ^a   Gansevoort, R T ^a   Reinhard, H ^d   Persson, F ^d   Lajer, M ^d   Rossing, P ^d,e,f   Heerspink, H J Lambers ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^d STENO DIABETES CENTER   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

2 HS glycoprotein; Albuminuria; Biomarkers; Chronic kidney disease; Collagen; eGFR; Proteomics; Risk score; Type 2 diabetes mellitus; Uromodulin

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN; FETUIN A; PEPTIDE;

AGED; AREA UNDER THE CURVE; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INTEGRATED DISCIMINATION INDEX; INVESTIGATIVE PROCEDURES; MACROALBUMINURIA; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; ALBUMINURIA; METHODOLOGY; MIDDLE AGED; PATHOLOGY; URINE;

AGED; ALBUMINURIA; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PROSPECTIVE STUDIES; PROTEOMICS;

MLCS; MLOWN;

EID: 84875597573     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2755-2     Document Type: Article

References (39)

1. Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:311-321
2. Remuzzi G, Schieppati A, Ruggenenti P (2002) Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 346:1145-1151
3. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A (1989) Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 32:219-226
4. Ritz E (2003) Albuminuria and vascular damage - the vicious twins. N Engl J Med 348:2349-2352
5. Ninomiya T, Perkovic V, de Galan BE et al (2009) Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20:1813-1821
6. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH (2004) Progression of nephropathy in type 2 diabetic patients. Kidney Int 66:1596-1605
7. Forsblom CM, Groop PH, Ekstrand A et al (1998) Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Diabetes Care 21:1932-1938
8. Hellemons ME, Kerschbaum J, Bakker SJ et al (2011) Validity of biomarkers predicting onset or progression of nephropathy in patients with type 2 diabetes: a systematic review. Diabet Med 29:567-577
9. Rossing K, Mischak H, Dakna M et al (2008) Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 19:1283-1290
10. Merchant ML, Perkins BA, Boratyn GM et al (2009) Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol 20:2065-2074
11. Mullen W, Delles C, Mischak H, COST EuroKUP action (2011) Urinary proteomics in the assessment of chronic kidney disease. Curr Opin Nephrol Hypertens 20:654-661
12. Good DM, Zurbig P, Argiles A et al (2010) Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 9:2424-2437
13. Pinto-Sietsma SJ, Janssen WM, Hillege HL, Navis G, de Zeeuw D, de Jong PE (2000) Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol 11:1882-1888
14. Reinhard H, Hansen PR, Persson F et al (2011) Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrol Dial Transplant 26:3242-3249
15. Zurbig P, Renfrow MB, Schiffer E et al (2006) Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis 27:2111-2125
16. Theodorescu D, Wittke S, Ross MM et al (2006) Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 7:230-240
17. Haubitz M, Good DM, Woywodt A et al (2009) Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics 8:2296-2307
18. Jantos-Siwy J, Schiffer E, Brand K et al (2009) Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res 8:268-281
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-470
20. Rohlfing CL, Little RR, Wiedmeyer HM et al (2000) Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care 23:187-191
21. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P (2004) Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 159:882-890
22. Steyerberg EW, Vickers AJ, Cook NR et al (2010) Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 21:128-138
23. Pencina MJ, D'Agostino RBS, D'Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157-172, discussion 207-12
24. Palmer AJ, Annemans L, Roze S et al (2004) Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 27:1897-1903
25. Fliser D, Novak J, Thongboonkerd V et al (2007) Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol 18:1057-1071
26. Mischak H, Rossing P (2010) Proteomic biomarkers in diabetic nephropathy - reality or future promise? Nephrol Dial Transplant 25:2843-2845
27. Babazono T, Nyumura I, Toya K et al (2009) Higher levels of urinary albumin excretion within the normal range predict faster decline in glomerular filtration rate in diabetic patients. Diabetes Care 32:1518-1520
28. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH (2001) Progression of diabetic nephropathy. Kidney Int 59:702-709
29. Gilstrap LG, Wang TJ (2012) Biomarkers and cardiovascular risk assessment for primary prevention: an update. Clin Chem 58:72-82
30. Otu HH, Can H, Spentzos D et al (2007) Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 30:638-643
31. Lapolla A, Seraglia R, Molin L et al (2009) Low molecular weight proteins in urines from healthy subjects as well as diabetic, nephropathic and diabetic-nephropathic patients: a MALDI study. J Mass Spectrom 44:419-425
32. Lynn KL, Marshall RD (1984) Excretion of Tamm-Horsfall glycoprotein in renal disease. Clin Nephrol 22:253-257
33. Chakraborty J, Below AA, Solaiman D (2004) Tamm-Horsfall protein in patients with kidney damage and diabetes. Urol Res 32:79-83
34. Rao PV, Lu X, Standley M et al (2007) Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care 30:629-637
35. Ben Ameur R, Molina L, Bolvin C et al (2010) Proteomic approaches for discovering biomarkers of diabetic nephropathy. Nephrol Dial Transplant 25:2866-2875
36. Nauta FL, Boertien WE, Bakker SJ et al (2011) Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care 34:975-981
37. Miyata T, Jadoul M, Kurokawa K, van Ypersele de Strihou C (1998) Beta-2 microglobulin in renal disease. J Am Soc Nephrol 9:1723-1735
38. Andersen S, Mischak H, Zurbig P, Parving HH, Rossing P (2010) Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol 11:29
39. Weissinger EM, Schiffer E, Hertenstein B et al (2007) Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 109:5511-5519